Nevro Corp
12
3
5
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
8.3%
1 terminated/withdrawn out of 12 trials
75.0%
-11.5% vs industry average
8%
1 trials in Phase 3/4
33%
1 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
SCS for Patient With Painful Diabetic Neuropathy and Peripheral Arterial Disease
Role: collaborator
Sacroiliac (SI) Joint Transfixing and Fusion: Meaningful Long Term Outcomes With Nevro1
Role: lead
Clinical Trial of MED HF10™ Spinal Cord Stimulation for the Treatment of Chronic Pain
Role: lead
Nerve Root Block in Spasticity
Role: collaborator
PDN Post Market, Multicenter, Prospective, Global Clinical Study
Role: lead
Pain and Neurological Function Improvements With 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy
Role: lead
Comparison of HF10 Therapy Combined With CMM to CMM Alone in the Treatment of Non-Surgical Refractory Back Pain
Role: lead
Comparison of 10 kHz SCS Combined With CMM to CMM Alone in the Treatment of Neuropathic Limb Pain
Role: lead
HF10 Treatment of Chronic Knee Pain
Role: lead
SCS for the Treatment Of Chronic Pain of the Upper Extremities
Role: lead
Clinical Trial of the Senza™ SCS System in the Treatment of Chronic Upper Limb and Neck Pain
Role: lead
Comparison of Senza to Commercial Spinal Cord Stimulation for the Treatment of Chronic Pain
Role: lead
All 12 trials loaded